Lactobacillus fermentum LF61 and Increased Immunoglobulin A Levels

• Limosilactobacillus fermentum LF61: A multidimensional study on safety and functionality from genomics to clinical application.

  • 2026-05
  • RCT · n = 49
  • Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 211
  • • Manfei Jin
    • Fei Xu
    • Yinhua Liu
    • Zhao Jiang

  • PubMed: 41655688
  • DOI: 10.1016/j.fct.2026.116002

  4 Insights on

  • Increased Immunoglobulin A Levels

  • High evidence
  • Clinical

  In a randomized, double-blind clinical trial (n = 49), daily intake of 3 × 10^10 CFU of LF61 for 8 weeks increased serum levels of the antimicrobial peptide LL-37 by 12.3% (p < 0.05), and IgA, IgG, and IgM by 18.7%, 15.2%, and 9.8%, respectively (p < 0.05).

  Effect

  Beneficial

  Effect size

  Small

  Significant

  Yes

  Dose

  3 × 10^10 CFU/day